Skip to main content

Table 3 Baseline antithrombotic therapy and cardiovascular medications

From: Characteristics and antithrombotic treatment patterns of patients with concomitant coronary artery disease and atrial fibrillation from Thailand’s COOL-AF registry

Therapy and medications CAD
(n = 557)
No CAD
(n = 2,904)
p-value
Antiplatelet use, n (%) 318 (57.1%) 589 (20.3%)  < 0.001
Single antiplatelet 245 (77.0%) 560 (95.1%)  
ASA 195 (79.6%) 506 (90.4%)  
P2Y12 inhibitors 50 (20.4%) 54 (9.6%)  
Dual antiplatelet 73 (23.0%) 26 (4.4%)  
Oral anticoagulants, n (%) 423 (75.9%) 2,183 (75.2%) 0.699
Warfarin 385 (91.0%) 1,991 (91.2%)  
NOACs 38 (9.0%) 192 (8.8%)  
Rate and rhythm control medications, n (%)
 Beta blocker 430 (77.2%) 1,994 (68.7%)  < 0.001
 Diltiazem 11 (2.0%) 72 (2.5%) 0.476
 Verapamil 4 (0.7%) 29 (1.0%) 0.533
 Digoxin 66 (11.8%) 477 (16.4%) 0.007
 Amiodarone 40 (7.2%) 259 (8.9%) 0.181
 Other AAD 5 (0.9%) 79 (2.7%) 0.010
Other medications, n (%)
 DHP-CCB 130 (23.3%) 727 (25.0%) 0.396
 PPI 194 (34.8%) 523 (18.0%)  < 0.001
 Statin 471 (84.6%) 1,572 (54.1%)  < 0.001
 ACEI 158 (28.4%) 616 (21.2%)  < 0.001
 ARB 172 (30.9%) 648 (22.3%)  < 0.001
  1. Data presented as number and percentage
  2. A p-value < 0.05 indicates statistical significance
  3. CAD, coronary artery disease; ASA, aspirin; NOACs, non-vitamin K antagonist oral anticoagulants; AAD, antiarrhythmic drug; DHP-CCB, dihydropyridine calcium channel blocker; PPI, proton pump inhibitor; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker